Posted by Michael Wonder on 22 Dec 2021
Deciphera announces approval of Qinlock in the United Kingdom for the treatment of fourth-line gastro-intestinal stromal tumour
21 December 2021 - Qinlock significantly reduced the risk of disease progression or death by 85% and showed clinically meaningful overall survival in the INVICTUS Phase 3 study.
Deciphera Pharmaceuticals today announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted marketing authorisation for Qinlock (ripretinib) in the UK for the treatment of adult patients with advanced gastro-intestinal stromal tumour who have received prior treatment with three or more kinase inhibitors, including imatinib.
